Evidence map›Paper›PMID 26562316›Full record

ReviewVaccine2016

Recombinant measles AIK-C vaccine strain expressing heterologous virus antigens.

Tetsuo Nakayama, Akihito Sawada, Yoshiaki Yamaji, Takashi Ito

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tetsuo NakayamaKitasato Institute for Life Sciences, Laboratory of Viral Infection I, Minato-ku, Tokyo 108-8641, Japan. Electronic address: tetsuo-n@lisci.kitasato-u.ac.jp.
Akihito SawadaKitasato Institute for Life Sciences, Laboratory of Viral Infection I, Minato-ku, Tokyo 108-8641, Japan.
Yoshiaki YamajiKitasato Institute for Life Sciences, Laboratory of Viral Infection I, Minato-ku, Tokyo 108-8641, Japan.
Takashi ItoKitasato Institute for Life Sciences, Laboratory of Viral Infection I, Minato-ku, Tokyo 108-8641, Japan.
Kitasato Institute Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Further attenuated measles vaccines were developed more than 50 years ago and have been used throughout the world. Recombinant measles vaccine candidates have been developed and express several heterologous virus protective antigens. Immunogenicity and protective actions were confirmed using experimental animals: transgenic mice, cotton rats, and primates. The recent development of measles vaccine-based vectored vaccine candidates has been reviewed and some information on recombinant measles vaccines expressing respiratory syncytial virus proteins has been shown and discussed.

Indexed as

Drug CarriersGene ExpressionAnimalsAntigensMeasles virusMice, TransgenicPrimatesRecombinant ProteinsRespiratory Syncytial VirusesRespiratory Syncytial Virus VaccinesSigmodontinaeTreatment OutcomeVaccines, AttenuatedVaccines, SyntheticAntigensDrug CarriersRecombinant ProteinsRespiratory Syncytial Virus VaccinesVaccines, AttenuatedVaccines, SyntheticAIK-C measles vaccineRecombinant virusRespiratory syncytial virusReverse genetics

Identifiers

PMID26562316
PMCPMC7115616
OpenAlexW2195800150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.